MoonLake Immunotherapeutics (MLTX) — Shareholders' Equity
| Fiscal Year | Shareholders' Equity | Change YoY |
|---|---|---|
| 2025 | $304.48M | -31.9% |
| 2024 | $446.82M | -9.9% |
| 2023 | $495.68M | +913.7% |
| 2022 | $48.90M | +519.9% |
| 2021 | -$11.65M | -362.8% |
| 2020 | -$2.52M | — |
| Fiscal Year | Shareholders' Equity | Change YoY |
|---|---|---|
| 2025 | $304.48M | -31.9% |
| 2024 | $446.82M | -9.9% |
| 2023 | $495.68M | +913.7% |
| 2022 | $48.90M | +519.9% |
| 2021 | -$11.65M | -362.8% |
| 2020 | -$2.52M | — |